Healthcare - Press Releases

Driving Sustainable Healthcare with "CARE" Strategy

SAN DIEGO, March 25, 2025 /PRNewswire/ -- Adcentrx Therapeutics("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life-threatening diseases, will present new data at the American Association for Cancer Research (AACR) Annual Meeting 2025, (April 25-30, 2025) in Chicago, IL.

SUZHOU, China, March 25, 2025 /PRNewswire/ -- From April 25 to 30, 2025, the American Association for Cancer Research (AACR) Annual Meeting will take place in Chicago. CStone will showcase its latest preclinical studies on five internally developed innovative candidates, including the trispecific antibody CS2009, the bispecific antibody CS2011, and three novel antibody-drug conjugates (ADCs) developed from CStone's proprietary ADC platform: CS5006, CS5007, and CS5005. The abstracts will be published in Cancer Research, the official journal of AACR, on April 11 (ET).

Accelerates Globalization of Innovative Products with Operating Cash Flow Surging 31.13% YoY

SHANGHAI, March 25, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative medicines and vaccines, today announced its financial results for the full year ended December 31, 2024, along with a corporate update.

JINAN, China, March 24, 2025 /PRNewswire/ -- Recently, Professor Sun Jinpeng's team at Shandong University and collaborators published a research paper titled "Metabolic signaling of ceramides through the FPR2 receptor inhibits adipocyte thermogenesis" in Science. This study employed high-throughput screening and animal models to identify FPR2, a G protein-coupled receptor (GPCR) expressed at the adipocyte plasma membrane, as a critical ceramide receptor. This work systematically elucidated how the ceramide-FPR2 signaling axis regulates adipocyte thermogenesis and uncovered the molecular basis of FPR2's specificity for ceramide recognition. These findings advance the understanding of ceramide's biological functions and open new avenues for developing targeted therapies against metabolic diseases.

NEPTUNE CITY, N.J., March 25, 2025 /PRNewswire/ -- Prominently featured in The Inner Circle, Rachel Elizabeth NeMoyer, MD, MPH is acknowledged as a Pinnacle Lifetime Member for her contributions to Advancing Thoracic Surgery with Compassion and Cutting-Edge Robotics.

COLUMBIA, Md., March 25, 2025 /PRNewswire/ -- Prominently featured in The Inner Circle, Phyllis Heffner, MD is being acknowledged as a Pinnacle Professional Member Inner Circle of Excellence for her contributions in the medical field.

In this first-of-its-kind partnership for its Dental Solutions business, Solventum, formerly 3M Health Care, is striving to focus on longevity and durability of permanent same-day restorative dental offerings, reaffirming its commitment to solving industry's toughest problems

SEATTLE, March 23, 2025 /PRNewswire/ --The surge in online supplement sales has led to a troubling rise in counterfeit products infiltrating e-commerce platforms, deceiving buyers with misleading packaging and false advertising. Mitolyn, Bioventra's brand, a well-established name in health and wellness, is issuing a consumer warning regarding unauthorized resellers distributing imitation versions of its product. The company has identified multiple fraudulent listings across online marketplaces, raising concerns about product authenticity and customer safety.

138 fourth-year NEOMED medical students have been matched with prestigious healthcare institutions in Ohio and throughout the U.S.

SHANGHAI, March 23, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for EVM14, a Tumor-Associated Antigen (TAA) vaccine. EVM14 is Everest's first internally developed mRNA therapeutic vaccine to receive FDA IND approval, marking a significant milestone in the Company's efforts to develop innovative mRNA therapeutics in oncology.

-- U.S.IND clearance and revaccination trial initiation supports the differentiated global opportunity for Clover's RSV PreF vaccine (SCB-1019) utilizing validated Trimer-Tag platform --

SAN FRANCISCO andSUZHOU, China, March 23, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the first participant has been successfully dosed with IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate, HER2 ADC) in a randomized, controlled, multicenter Phase 3 clinical trial (HeriCare-Ovarian01), for platinum-resistant ovarian cancer (PROC) with HER2 expression.

SUZHOU, China, March 23, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of aType II variation applicationto the European Medicines Agency (EMA) forsugemalimab. The application seeks approval for the treatment ofpatients with unresectable stage III non-small cell lung cancer (NSCLC) who have not progressed following concurrent or sequential platinum-based chemoradiotherapy (CRT). This marks CStone's second regulatory submission for sugemalimab to the EMA, following its initial approval in Europe for metastatic squamous and non-squamous NSCLC in 2024. If this new indication is approved, sugemalimab would address a critical unmet need in stage III NSCLC, where only one PD-L1 antibody is currently approved in Europe. The drug's dual utility in stage III and IV NSCLC could solidify its role as a cornerstoneimmunotherapy in lung cancer.

SHANGHAI, March 23, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received 2025 CDMO Leadership Awards in the "Biologics - Global" category. It has also been recognized for excellence in "Best Scientific Expertise", "Best Seamless Delivery Across Phases", "Best Innovative Approach to Technology and Process Execution", making it the most lauded company in the ceremony.

Achieves International Recognition with HIMSS Award for Excellence in Smart Healthcare

HONG KONG, March 23, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced on March 21st, 2025 its financial results for fiscal year 2024, reporting total revenue of RMB 2.7 billion, representing an 11.2% year-over-year increase. Notably, the company's adjusted net profit reached RMB 17.2 million, a significant 139% growth compared to 2023, driven by ongoing technology enhancements and improvements in operating efficiency.

BOSTON, March 23, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has agreed to sell an aggregate of 10,250,000 shares of its common stock and warrants to purchase up to 10,250,000 shares of common stock priced at-the-market under Nasdaq rules, at a purchase price of $0.98 per share and associated warrant. The warrants will have an exercise price of $0.86 per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance. All of the shares of common stock and associated warrants are being offered by the Company. The offering is expected to close on March 25, 2025, subject to satisfaction of customary closing conditions.

SEATTLE, March 24, 2025 /PRNewswire/ -- The surge in online supplement sales has led to a troubling rise in counterfeit products infiltrating e-commerce platforms, deceiving buyers with misleading packaging and false advertising. PurDentix, Bioventra's brand, a well-established name in health and wellness, is issuing a consumer warning regarding unauthorized resellers distributing imitation versions of its product. The company has identified multiple fraudulent listings across online marketplaces, raising concerns about product authenticity and customer safety.

TOKYO, March 24, 2025 /PRNewswire/ -- The long-term care robot portal site management office released the English version of the "Long-term Care Tech Portal" (https://robotcare.jp/en/home/index?type=pw), a portal site providing information on state-of-the-art care and age tech in Japan.

TOKYO, March 24, 2025 /PRNewswire/ -- The long-term care robot portal site management office released the English version of the "Long-term Care Tech Portal" (https://robotcare.jp/en/home/index?type=pw), a portal site providing information on state-of-the-art care and age tech in Japan.

STOCKHOLM, March 24, 2025 /PRNewswire/ -- The hygiene and health companyEssity will publish its interim report for quarter 1, 2025 on April 24 at approximately 07:00 CET. President and CEO Magnus Groth and Executive Vice President and CFO Fredrik Rystedt will present the interim report at a live webcast and teleconference at 09:00 CET the same day.

STOCKHOLM, March 24, 2025 /PRNewswire/ -- The hygiene and health companyEssity will publish its interim report for quarter 1, 2025 on April 24 at approximately 07:00CET. President and CEO Magnus Groth and Executive Vice President and CFO Fredrik Rystedt will present the interim report at a live webcast and teleconference at 09:00 CET the same day.

MILAN, March 24, 2025 /PRNewswire/ -- Newronika, a leader in neuromodulation and adaptive deep brain stimulation (DBS) technology, announced today that it has received CE Mark approval for its AlphaDBS device, a next-generation closed-loop DBS system that dynamically adjusts stimulation based on real-time brain signals. This approval enables the company to commercialize AlphaDBS in Europe, bringing an innovative treatment option to patients living with Parkinson's disease and other neurological disorders.